Nexalin Technology, Inc. (NXL), Wednesday announced additional positive clinical data, demonstrating that its proprietary 15 milliamp Gen-2 Nexalin DIFS technology showed improves cognitive performance and enhances brain network connectivity in patients with mild Alzheimer's disease.
Additionally, the patients showed a significant improvement in Mini-Mental State Examination and Montreal Cognitive Assessment scores compared to the sham group.
The device also enhanced functional connectivity between the hippocampus and key cortical regions, increased functional connectivity across broader cognitive networks, and improved connectivity between the hippocampus and middle cingulate gyrus.
The findings, published in Radiology, further highlights the company's long term commitment to deliver safe, and effective alternatives to pharmacologic treatments for neurodegenerative conditions and their associated costs and side effects.
Currently, NXL is surging 96.12 percent, to $1.83 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.